Table 3 Adverse events
No. (%) | Any emergent adverse event (n = 38) | Treatment-related AEs (n = 38) | ||
|---|---|---|---|---|
Grade 3–4a | Any grade | Grade 3–4a | Any grade | |
Neutropenia | 15 (39.5) | 29 (76.3) | 11 (28.9) | 25 (65.8) |
Leukopenia | 5 (13.2) | 27 (71.1) | 3 (7.9) | 25 (65.8) |
Lymphopenia | 5 (13.2) | 23 (60.5) | 3 (7.9) | 21 (55.3) |
Thrombocytopenia | 10 (26.3) | 21 (55.3) | 4 (10.5) | 17 (44.7) |
Anemia | 3 (7.9) | 20 (52.6) | 0 | 17 (44.7) |
FT3/FT4 elevated | 0 | 18 (47.4) | 0 | 18 (47.4) |
Pyrexia | 3 (7.9) | 15 (39.5) | 0 | 5 (13.2) |
TSH elevated | 0 | 16 (42.1) | 0 | 16 (42.1) |
APTT shorten | 0 | 15 (39.5) | 0 | 15 (39.5) |
Hypoproteinemia | 0 | 14 (36.8) | 0 | 14 (36.8) |
Transaminase elevated | 2 (5.3) | 13 (34.2) | 0 | 10 (26.3) |
Plasma fibrinogen elevated | 0 | 13 (34.2) | 0 | 9 (23.7) |
Nausea and vomiting | 0 | 10 (26.3) | 0 | 10 (26.3) |
Creatine kinase elevated | 0 | 10 (26.3) | 0 | 10 (26.3) |
HBDH elevated | 0 | 9 (23.7) | 0 | 9 (23.7) |
Hypothyroidism | 0 | 7 (18.4) | 0 | 7 (18.4) |
Hyperbilirubinemia | 2 (5.3) | 6 (15.8) | 0 | 5 (13.2) |
Proteinuria | 0 | 6 (15.8) | 0 | 6 (15.8) |
Fatigue | 0 | 6 (15.8) | 0 | 6 (15.8) |
Hyperglycemia | 0 | 5 (13.2) | 0 | 5 (13.2) |
Creatinine elevated | 0 | 5 (13.2) | 0 | 5 (13.2) |
Upper respiratory tract infection | 0 | 5 (13.2) | 0 | 5 (13.2) |
Hypothyroidism | 0 | 4 (10.5) | 0 | 4 (10.5) |
Neuralgia | 0 | 4 (10.5) | 0 | 2 (5.3) |
Rash | 0 | 3 (7.9) | 0 | 3 (7.9) |
Hematemesis | 0 | 3 (7.9) | 0 | 3 (7.9) |
Hypertension | 0 | 3 (7.9) | 0 | 3 (7.9) |
Interstitial pneumonia | 2 (5.3) | 3 (7.9) | 2 (5.3) | 3 (7.9) |
Plasma lipase elevated | 0 | 2 (5.3) | 0 | 2 (5.3) |
Herpes zoster | 0 | 2 (5.3) | 0 | 2 (5.3) |
Hyperuricemia | 0 | 2 (5.3) | 0 | 2 (5.3) |
Generalized edema | 1 (2.6) | 2 (5.3) | 0 | 2 (5.3) |
Mucositis oral | 0 | 2 (5.3) | 0 | 2 (5.3) |
Infusion‐related reaction | 0 | 2 (5.3) | 0 | 2 (5.3) |
Diarrhea | 0 | 2 (5.3) | 0 | 2 (5.3) |
Gastric ulcer | 1 (2.6) | 2 (5.3) | 1 (2.6) | 1 (2.6) |
Abdominal pain | 1 (2.6) | 2 (5.3) | 1 (2.6) | 1 (2.6) |
Weight gain | 1 (2.6) | 2 (5.3) | 0 | 1 (2.6) |
Plasma amylase elevated | 0 | 1 (2.6) | 0 | 1 (2.6) |
Exfoliative dermatitis | 1 (2.6) | 1 (2.6) | 1 (2.6) | 1 (2.6) |
Gastritis | 0 | 1 (2.6) | 0 | 1 (2.6) |
Blepharoptosis | 0 | 1 (2.6) | 0 | 1 (2.6) |
Blurred vision | 0 | 1 (2.6) | 0 | 1 (2.6) |
Headache | 0 | 1 (2.6) | 0 | 1 (2.6) |
